Cooper Reports Q3 Earnings: Revenue and EPS Growth Driven by CooperSurgical
The Cooper Companies (COO) reported third-quarter earnings for fiscal year 2026, with revenue reaching $1.066 billion—up 1% organically due to growth in its CooperSurgical segment despite flat performance at CooperVision. Non-GAAP diluted EPS rose by 4% year-over-year to $1.15 and exceeded expectations for the 11th consecutive quarter. Free cash flow hit a record high of $273 million, contributing to total free cash flow of $528 million through nine months. CooperSurgical revenue grew organically by 3%, driven primarily by fertility services and medical devices, while CooperVision saw flat performance due to inventory reductions in the U.S. channel. The company also recognized a discrete tax benefit of $307.2 million from an HMRC examination related to intellectual property transfers. Looking ahead, management guided for Q4 revenue between $1.057 billion and $1.080 billion with non-GAAP EPS expected in the range of $1.05–$1.09.
Tickers: $COO
Topics: eps free_cash_flow margin_changes revenue